CY1116062T1 - Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα - Google Patents

Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα

Info

Publication number
CY1116062T1
CY1116062T1 CY20151100205T CY151100205T CY1116062T1 CY 1116062 T1 CY1116062 T1 CY 1116062T1 CY 20151100205 T CY20151100205 T CY 20151100205T CY 151100205 T CY151100205 T CY 151100205T CY 1116062 T1 CY1116062 T1 CY 1116062T1
Authority
CY
Cyprus
Prior art keywords
eye diseases
preventive
supplemental
therapeutic
education
Prior art date
Application number
CY20151100205T
Other languages
Greek (el)
English (en)
Inventor
Philip Hass
Yin Jianping
Kenneth Katschke Jr
Micah Steffek
Christian Wiesmann
Lookeren Campagne Menno Van
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116062(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of CY1116062T1 publication Critical patent/CY1116062T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
CY20151100205T 2007-05-23 2015-02-27 Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα CY1116062T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
EP08756130.4A EP2152755B1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Publications (1)

Publication Number Publication Date
CY1116062T1 true CY1116062T1 (el) 2017-02-08

Family

ID=39638868

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100205T CY1116062T1 (el) 2007-05-23 2015-02-27 Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα

Country Status (28)

Country Link
US (6) US8007791B2 (OSRAM)
EP (1) EP2152755B1 (OSRAM)
JP (4) JP5416695B2 (OSRAM)
KR (1) KR101540126B1 (OSRAM)
CN (3) CN104367999A (OSRAM)
AR (1) AR066660A1 (OSRAM)
AU (1) AU2008256835B2 (OSRAM)
BR (1) BRPI0811142A8 (OSRAM)
CA (1) CA2683498A1 (OSRAM)
CL (1) CL2008001498A1 (OSRAM)
CY (1) CY1116062T1 (OSRAM)
DK (1) DK2152755T3 (OSRAM)
ES (1) ES2533242T3 (OSRAM)
HK (1) HK1207327A1 (OSRAM)
HR (1) HRP20150281T1 (OSRAM)
IL (2) IL201476A (OSRAM)
MX (1) MX2009012422A (OSRAM)
PE (1) PE20090294A1 (OSRAM)
PH (1) PH12013500992B1 (OSRAM)
PL (1) PL2152755T3 (OSRAM)
PT (1) PT2152755E (OSRAM)
RS (1) RS53901B1 (OSRAM)
RU (2) RU2522976C2 (OSRAM)
SG (1) SG10201401404RA (OSRAM)
SI (1) SI2152755T1 (OSRAM)
TW (2) TW201417829A (OSRAM)
WO (1) WO2008147883A1 (OSRAM)
ZA (1) ZA200907028B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
KR20180002911A (ko) * 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
AU2007313685C1 (en) 2006-11-02 2015-09-17 Genentech, Inc. Humanized anti-Factor D antibodies
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
EP2342190A1 (en) * 2008-09-02 2011-07-13 Novartis AG Bicyclic kinase inhibitors
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
ES2894940T3 (es) * 2010-08-05 2022-02-16 Forsight Vision4 Inc Aparato para tratar un ojo
NZ610067A (en) * 2010-11-01 2015-05-29 Genentech Inc Predicting progression to advanced age-related macular degeneration using a polygenic score
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
KR20150036481A (ko) 2012-07-12 2015-04-07 노파르티스 아게 보체 경로 조절제 및 그의 용도
CN110256559B (zh) 2012-07-25 2023-05-26 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
US20160237146A1 (en) * 2013-10-07 2016-08-18 Massachusetts Eye And Ear Infirmary Methods of Preventing or Reducing Photoreceptor Cell Death
AU2014339890A1 (en) * 2013-10-25 2016-06-02 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
EA201692109A1 (ru) * 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
PT3352776T (pt) * 2015-09-23 2025-06-27 Sangamo Therapeutics Inc Repressores de htt e utilizações dos mesmos
WO2017075170A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Methods of measuring factor d activity and potency of factor d inhibitors
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
RU2750285C2 (ru) 2015-10-30 2021-06-25 Дженентек, Инк. АНТИТЕЛА ПРОТИВ НtrА1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
DK3394089T3 (da) * 2015-12-23 2021-11-01 eleva GmbH Polypeptider til inhibering af komplementaktivering
JP2019506159A (ja) 2016-01-20 2019-03-07 ヴィトリサ セラピューティクス， インコーポレイテッド Ｄ因子を阻害するための組成物および方法
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
JP2020507581A (ja) 2017-02-10 2020-03-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗ｄ因子抗体及びその使用
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
WO2021009777A2 (en) * 2019-07-18 2021-01-21 Pandorum Technologies Private Limited Methods of stem cell culture for obtaining products, and implementations thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2316175T3 (es) 1997-11-21 2009-04-01 Genentech, Inc. Antigenos especificos de plaquetas y sus usos farmacologicos.
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
JP2002502589A (ja) 1998-02-09 2002-01-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４５個のヒト分泌タンパク質
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
ATE412431T1 (de) * 1998-02-20 2008-11-15 Tanox Inc Inhibitoren der komplement-aktivierung
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
EP1108019A2 (en) 1998-08-27 2001-06-20 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
KR100468977B1 (ko) 1998-12-16 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
KR20010081089A (ko) * 1998-12-21 2001-08-25 에드워드 에이. 맥더모 2세, 로이드 제이. 오울드 절단된 ｖｅｇｆ-ｄ에 대한 항체 및 그것의 이용
DK1484338T3 (da) 1998-12-22 2007-06-11 Genentech Inc Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst
JP2004516227A (ja) 1999-03-08 2004-06-03 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物と方法
RU2244748C2 (ru) 1999-03-11 2005-01-20 РМФ Диктажен С.А. Адгезивные молекулы сосудов и модуляция их функций
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
UA72943C2 (uk) 1999-11-02 2005-05-16 Ульяновскій Государствєнний Тєхніческій Унівєрсітєт Спосіб очищення рідини від феромагнітних частинок (варіанти) і пристрій для його здійснення (варіанти)
JP2003514541A (ja) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １８個のヒト分泌タンパク質
EP1672070A3 (en) 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
AU2001271973A1 (en) 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003258714A1 (en) 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
KR20180002911A (ko) * 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AU2007313685C1 (en) * 2006-11-02 2015-09-17 Genentech, Inc. Humanized anti-Factor D antibodies
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
CN101754980B (zh) 2014-10-29
TW201417829A (zh) 2014-05-16
BRPI0811142A8 (pt) 2018-12-18
AU2008256835A1 (en) 2008-12-04
KR101540126B1 (ko) 2015-07-28
RU2522976C2 (ru) 2014-07-20
HK1139161A1 (en) 2010-09-10
CN101754980A (zh) 2010-06-23
AR066660A1 (es) 2009-09-02
JP2016145205A (ja) 2016-08-12
ZA200907028B (en) 2010-12-29
CA2683498A1 (en) 2008-12-04
JP2014087346A (ja) 2014-05-15
US20130302333A1 (en) 2013-11-14
TW200904471A (en) 2009-02-01
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23
EP2152755B1 (en) 2014-12-31
WO2008147883A1 (en) 2008-12-04
US8497094B2 (en) 2013-07-30
MX2009012422A (es) 2009-12-04
JP2010528047A (ja) 2010-08-19
KR20100033973A (ko) 2010-03-31
US8268310B2 (en) 2012-09-18
JP5416695B2 (ja) 2014-02-12
CN107096029B (zh) 2021-02-26
HRP20150281T1 (hr) 2015-04-10
CN104367999A (zh) 2015-02-25
WO2008147883A8 (en) 2013-05-23
IL201476A0 (en) 2010-05-31
PL2152755T3 (pl) 2015-06-30
ES2533242T3 (es) 2015-04-08
IL201476A (en) 2016-11-30
IL248552A0 (en) 2016-12-29
US20110282034A1 (en) 2011-11-17
EP2152755A1 (en) 2010-02-17
JP2017197577A (ja) 2017-11-02
PT2152755E (pt) 2015-04-01
CN107096029A (zh) 2017-08-29
US20160272726A1 (en) 2016-09-22
RU2009147744A (ru) 2011-06-27
SG10201401404RA (en) 2014-08-28
SI2152755T1 (sl) 2015-05-29
RU2014113046A (ru) 2015-10-10
US20090181017A1 (en) 2009-07-16
PE20090294A1 (es) 2009-03-27
PH12013500992B1 (en) 2018-12-14
RS53901B1 (sr) 2015-08-31
HK1207327A1 (en) 2016-01-29
PH12013500992A1 (en) 2016-01-25
US8007791B2 (en) 2011-08-30
US20130052685A1 (en) 2013-02-28
CL2008001498A1 (es) 2009-06-12
TWI419704B (zh) 2013-12-21
US20180079826A1 (en) 2018-03-22
DK2152755T3 (en) 2015-03-02

Similar Documents

Publication Publication Date Title
CY1116062T1 (el) Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
WO2019032662A8 (en) Clec9a binding agents and use thereof
MX2015012435A (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2019001021A (es) Formulaciones de liposomas.
PH12013501436A1 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
CY1120213T1 (el) Antαγωνιστες φθοριωμενης ιντεγκρινης
MX2010003949A (es) N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
JO3156B1 (ar) ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
BRPI0820343A2 (pt) Anticorpos de antifator b e seus usos
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
MX2016009600A (es) Agentes para utilizarse en el tratamiento de la inflamacion de retina.
HK1198514A1 (en) Substituted heterocyclic compounds for disease treatment
CL2018001370A1 (es) Derivados novedosos de diamino piridina
TW200744627A (en) Methods for the treatment of macular degeneration and related eye conditions
ZA201906153B (en) Pharmaceutical compositions for combination therapy
TW200744670A (en) Methods for the treatment of macular degeneration and related eye conditions
HK1144291A (en) Anti-factor b antibodies and their uses